{"nctId":"NCT03317444","briefTitle":"Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease","startDateStruct":{"date":"2017-09-26","type":"ACTUAL"},"conditions":["Metabolic Acidosis"],"count":217,"armGroups":[{"label":"TRC101","type":"EXPERIMENTAL","interventionNames":["Drug: TRC101"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"TRC101","otherNames":["Veverimer"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Blood bicarbonate level of 12 to 20 mEq/L.\n* Estimated glomerular filtration rate (eGFR) of 20 to 40 mL/min/1.73m2.\n* Stable kidney function defined as \\<=20% variability in eGFR during screening period.\n\nKey Exclusion Criteria:\n\n* Any level of low blood bicarbonate during the screening period that in the opinion of the Investigator, requires emergency intervention or evaluation for an acute acidotic process.\n* Anuria, dialysis, acute kidney injury, or history of acute kidney insufficiency within 3 months prior to screening.\n* Heart failure with maximum New York Heart Association (NYHA) Class IV symptoms or that required hospitalization during the preceding 6 months.\n* Heart or kidney transplant.\n* Chronic obstructive pulmonary disease (COPD) that is treated with chronic oral steroids, that requires the subject to be on oxygen, or that required hospitalization within the previous 6 months.\n* Change in doses to alkali therapy in the 4 weeks prior to screening.\n* History or current diagnosis of diabetic gastroparesis, bowel obstruction, swallowing disorders, inflammatory bowel disease, major gastrointestinal surgery, frequent diarrhea or active gastric/duodenal ulcers.\n* Serum calcium \\<= 8.0 mg/dL at screening.\n* Planned initiation of renal replacement therapy within 12 weeks following randomization.\n* Use of polymeric binder drugs within 14 days prior to screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Subjects With Change From Baseline in Serum Bicarbonate of ≥ 4 mEq/L or Serum Bicarbonate Within the Normal Range","description":"Composite endpoint of the percentage of subjects having a change from baseline in serum bicarbonate ≥ 4 mEq/L or having serum bicarbonate in the normal range (22 - 29 mEq/L) at the end of treatment (Week 12 Visit).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2","spread":null},{"groupId":"OG001","value":"22.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.8","spread":null},{"groupId":"OG001","value":"21.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"16.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Treatment in Serum Bicarbonate","description":"Mean change from baseline to end of treatment (Week 12 Visit) in serum bicarbonate","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.42","spread":null},{"groupId":"OG001","value":"1.78","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":124},"commonTop":["Hyperkalaemia","Diarrhoea","Headache"]}}}